The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PEG-modified Drugs Market Research Report 2024
Synopsis
Polyethylene glycol modified drug refers to a method of drug modification that combines polyethylene glycol molecules with drug molecules to improve the properties, pharmacokinetics and pharmacodynamic properties of drugs. This modification is often used to improve drug solubility, stability, bioavailability, and drug distribution.
Global PEG-modified Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs market research.
Key companies engaged in the PEG-modified Drugs industry include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of PEG-modified Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PEG-modified Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Segment by Application
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The PEG-modified Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Polyethylene glycol modified drug refers to a method of drug modification that combines polyethylene glycol molecules with drug molecules to improve the properties, pharmacokinetics and pharmacodynamic properties of drugs. This modification is often used to improve drug solubility, stability, bioavailability, and drug distribution.
Global PEG-modified Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs market research.
Key companies engaged in the PEG-modified Drugs industry include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of PEG-modified Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PEG-modified Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Segment by Application
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The PEG-modified Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PEG-modified Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 PEG Amidation
1.2.3 PEGylation
1.2.4 PEG Peptidation
1.2.5 PEG Etherification
1.2.6 Other Combinations
1.3 Market by Application
1.3.1 Global PEG-modified Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer Treatment
1.3.3 Diabetes Treatment
1.3.4 Immunomodulatory
1.3.5 Anti-inflammatory Treatment
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PEG-modified Drugs Market Perspective (2018-2029)
2.2 PEG-modified Drugs Growth Trends by Region
2.2.1 Global PEG-modified Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 PEG-modified Drugs Historic Market Size by Region (2018-2023)
2.2.3 PEG-modified Drugs Forecasted Market Size by Region (2024-2029)
2.3 PEG-modified Drugs Market Dynamics
2.3.1 PEG-modified Drugs Industry Trends
2.3.2 PEG-modified Drugs Market Drivers
2.3.3 PEG-modified Drugs Market Challenges
2.3.4 PEG-modified Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PEG-modified Drugs Players by Revenue
3.1.1 Global Top PEG-modified Drugs Players by Revenue (2018-2023)
3.1.2 Global PEG-modified Drugs Revenue Market Share by Players (2018-2023)
3.2 Global PEG-modified Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PEG-modified Drugs Revenue
3.4 Global PEG-modified Drugs Market Concentration Ratio
3.4.1 Global PEG-modified Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PEG-modified Drugs Revenue in 2022
3.5 PEG-modified Drugs Key Players Head office and Area Served
3.6 Key Players PEG-modified Drugs Product Solution and Service
3.7 Date of Enter into PEG-modified Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PEG-modified Drugs Breakdown Data by Type
4.1 Global PEG-modified Drugs Historic Market Size by Type (2018-2023)
4.2 Global PEG-modified Drugs Forecasted Market Size by Type (2024-2029)
5 PEG-modified Drugs Breakdown Data by Application
5.1 Global PEG-modified Drugs Historic Market Size by Application (2018-2023)
5.2 Global PEG-modified Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America PEG-modified Drugs Market Size (2018-2029)
6.2 North America PEG-modified Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America PEG-modified Drugs Market Size by Country (2018-2023)
6.4 North America PEG-modified Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PEG-modified Drugs Market Size (2018-2029)
7.2 Europe PEG-modified Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe PEG-modified Drugs Market Size by Country (2018-2023)
7.4 Europe PEG-modified Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PEG-modified Drugs Market Size (2018-2029)
8.2 Asia-Pacific PEG-modified Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific PEG-modified Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific PEG-modified Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PEG-modified Drugs Market Size (2018-2029)
9.2 Latin America PEG-modified Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America PEG-modified Drugs Market Size by Country (2018-2023)
9.4 Latin America PEG-modified Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PEG-modified Drugs Market Size (2018-2029)
10.2 Middle East & Africa PEG-modified Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa PEG-modified Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa PEG-modified Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck Sharp & Dohme
11.1.1 Merck Sharp & Dohme Company Detail
11.1.2 Merck Sharp & Dohme Business Overview
11.1.3 Merck Sharp & Dohme PEG-modified Drugs Introduction
11.1.4 Merck Sharp & Dohme Revenue in PEG-modified Drugs Business (2018-2023)
11.1.5 Merck Sharp & Dohme Recent Development
11.2 Baxalta Inc.
11.2.1 Baxalta Inc. Company Detail
11.2.2 Baxalta Inc. Business Overview
11.2.3 Baxalta Inc. PEG-modified Drugs Introduction
11.2.4 Baxalta Inc. Revenue in PEG-modified Drugs Business (2018-2023)
11.2.5 Baxalta Inc. Recent Development
11.3 Amgen Inc.
11.3.1 Amgen Inc. Company Detail
11.3.2 Amgen Inc. Business Overview
11.3.3 Amgen Inc. PEG-modified Drugs Introduction
11.3.4 Amgen Inc. Revenue in PEG-modified Drugs Business (2018-2023)
11.3.5 Amgen Inc. Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche PEG-modified Drugs Introduction
11.4.4 Roche Revenue in PEG-modified Drugs Business (2018-2023)
11.4.5 Roche Recent Development
11.5 UCB S.A.
11.5.1 UCB S.A. Company Detail
11.5.2 UCB S.A. Business Overview
11.5.3 UCB S.A. PEG-modified Drugs Introduction
11.5.4 UCB S.A. Revenue in PEG-modified Drugs Business (2018-2023)
11.5.5 UCB S.A. Recent Development
11.6 Enzon
11.6.1 Enzon Company Detail
11.6.2 Enzon Business Overview
11.6.3 Enzon PEG-modified Drugs Introduction
11.6.4 Enzon Revenue in PEG-modified Drugs Business (2018-2023)
11.6.5 Enzon Recent Development
11.7 Horizon Pharma Plc
11.7.1 Horizon Pharma Plc Company Detail
11.7.2 Horizon Pharma Plc Business Overview
11.7.3 Horizon Pharma Plc PEG-modified Drugs Introduction
11.7.4 Horizon Pharma Plc Revenue in PEG-modified Drugs Business (2018-2023)
11.7.5 Horizon Pharma Plc Recent Development
11.8 Biogen Inc.
11.8.1 Biogen Inc. Company Detail
11.8.2 Biogen Inc. Business Overview
11.8.3 Biogen Inc. PEG-modified Drugs Introduction
11.8.4 Biogen Inc. Revenue in PEG-modified Drugs Business (2018-2023)
11.8.5 Biogen Inc. Recent Development
11.9 Qilu Pharmaceutical Co., Ltd.
11.9.1 Qilu Pharmaceutical Co., Ltd. Company Detail
11.9.2 Qilu Pharmaceutical Co., Ltd. Business Overview
11.9.3 Qilu Pharmaceutical Co., Ltd. PEG-modified Drugs Introduction
11.9.4 Qilu Pharmaceutical Co., Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.9.5 Qilu Pharmaceutical Co., Ltd. Recent Development
11.10 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
11.10.1 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Company Detail
11.10.2 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Business Overview
11.10.3 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. PEG-modified Drugs Introduction
11.10.4 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.10.5 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Recent Development
11.11 Changchun Genescience Pharmaceutical Co., Ltd.
11.11.1 Changchun Genescience Pharmaceutical Co., Ltd. Company Detail
11.11.2 Changchun Genescience Pharmaceutical Co., Ltd. Business Overview
11.11.3 Changchun Genescience Pharmaceutical Co., Ltd. PEG-modified Drugs Introduction
11.11.4 Changchun Genescience Pharmaceutical Co., Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.11.5 Changchun Genescience Pharmaceutical Co., Ltd. Recent Development
11.12 Xiamen Amoytop Biotech Co., Ltd.
11.12.1 Xiamen Amoytop Biotech Co., Ltd. Company Detail
11.12.2 Xiamen Amoytop Biotech Co., Ltd. Business Overview
11.12.3 Xiamen Amoytop Biotech Co., Ltd. PEG-modified Drugs Introduction
11.12.4 Xiamen Amoytop Biotech Co., Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.12.5 Xiamen Amoytop Biotech Co., Ltd. Recent Development
11.13 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.13.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Detail
11.13.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
11.13.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PEG-modified Drugs Introduction
11.13.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.13.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Development
11.14 Hansoh Pharmaceuticak Group Co.,Ltd.
11.14.1 Hansoh Pharmaceuticak Group Co.,Ltd. Company Detail
11.14.2 Hansoh Pharmaceuticak Group Co.,Ltd. Business Overview
11.14.3 Hansoh Pharmaceuticak Group Co.,Ltd. PEG-modified Drugs Introduction
11.14.4 Hansoh Pharmaceuticak Group Co.,Ltd. Revenue in PEG-modified Drugs Business (2018-2023)
11.14.5 Hansoh Pharmaceuticak Group Co.,Ltd. Recent Development
11.15 SunBio
11.15.1 SunBio Company Detail
11.15.2 SunBio Business Overview
11.15.3 SunBio PEG-modified Drugs Introduction
11.15.4 SunBio Revenue in PEG-modified Drugs Business (2018-2023)
11.15.5 SunBio Recent Development
11.16 Xiamen Sano banger Biotechnology Co., Ltd
11.16.1 Xiamen Sano banger Biotechnology Co., Ltd Company Detail
11.16.2 Xiamen Sano banger Biotechnology Co., Ltd Business Overview
11.16.3 Xiamen Sano banger Biotechnology Co., Ltd PEG-modified Drugs Introduction
11.16.4 Xiamen Sano banger Biotechnology Co., Ltd Revenue in PEG-modified Drugs Business (2018-2023)
11.16.5 Xiamen Sano banger Biotechnology Co., Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
